NON-HORMONAL COMPOSITIONS AND METHODS FOR MALE CONTRACEPTION COMPRISING (R)-SILODOSIN

(19)

(11)

EP 3 562 485 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	19.08.2020 Bulletin 2020/34

(45)	Mention of the grant of the patent:
	01.07.2020 Bulletin 2020/27

(21)	Application number: 19714150.0

(22)	Date of filing: 22.03.2019

(51)

International Patent Classification (IPC):

A61K 31/4045^(2006.01)
A61K 9/22^(2006.01)
A61P 15/16^(2006.01)

A61K 45/06^(2006.01)
A61K 9/50^(2006.01)

(86)	International application number:
	PCT/EP2019/057267

(87)	International publication number:
	WO 2019/180217 (26.09.2019 Gazette 2019/39)

(54)	NON-HORMONAL COMPOSITIONS AND METHODS FOR MALE CONTRACEPTION COMPRISING (R)-SILODOSIN NICHT-HORMONELLE ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MÄNNLICHEN KONTRAZEPTION ENTHALTEND (R)-SILODOSIN COMPOSITIONS ET PROCÉDÉS NON HORMONAUX POUR LA CONTRACEPTION MASCULINE AVEC (R)-SILODOSIN

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Validation States:
	KH MA TN

(30)

Priority:

23.03.2018 EP 18305328
23.03.2018 US 201862763129 P

(43)	Date of publication of application:
	06.11.2019 Bulletin 2019/45

(60)	Divisional application:
	20182691.4

(73)	Proprietor: Laboratoires Major
	75116 Paris (FR)

(72)	Inventors:
	EL GLAOUI, Guillaume 75008 Paris (FR) EL GLAOUI, Medhi 75008 Paris (FR) PERRIN, Philippe 75015 Paris (FR) DROUPY, Stéphane 30900 Nîmes (FR) AGATHON-MERIAU, Véronique 92500 Rueil-Malmaison (FR)

(74)	Representative: Icosa
	83 avenue Denfert-Rochereau 75014 Paris 75014 Paris (FR)

(56)

References cited: :

CN-B- 102 283 816

BHAT G ET AL: "BKP 02 Prospective double blind randomised study to evaluate the efficacy of Siliodosin 8 mg as on demand, reversible, male oral contraceptive", INDIAN JOURNAL OF UROLOGY, MEDKNOW PUBLICATIONS AND MEDIA PVT. LTD, IN , vol. 34, no. 5, Supplement 1 1 January 2018 (2018-01-01), page S7, XP009507905, ISSN: 1998-3824 Retrieved from the Internet: URL:http://www.indianjurol.com/text.asp?20 18/34/5/7/222931
JIN WANG ET AL: "Assessment of Tamsulosin as a Potential Male Contraceptive in Healthy Volunteers", UROLOGY., vol. 80, no. 3, 1 September 2012 (2012-09-01), pages 614-617, XP055240673, US ISSN: 0090-4295, DOI: 10.1016/j.urology.2012.06.003 cited in the application
CHEN Y ET AL: "Blockade of alpha1A-adrenoceptor: A novel possible strategy for male contraception", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 73, no. 2, 1 August 2009 (2009-08-01) , pages 140-141, XP026124106, ISSN: 0306-9877, DOI: 10.1016/J.MEHY.2009.02.022 [retrieved on 2009-05-08]
KOBAYASHI K ET AL: "ORGASM IS PRESERVED REGARDLESS OF EJACULATORY DYSFUNCTION WITH SELECTIVE ALPHA-1A-BLOCKER ADMINISTRATION", EUROPEAN UROLOGY SUPPLEMENTS, ELSEVIER BV, NL, vol. 7, no. 3, 1 March 2008 (2008-03-01), page 186, XP022610457, ISSN: 1569-9056, DOI: 10.1016/S1569-9056(08)60457-1 [retrieved on 2008-03-01]
KJAERGAARD N ET AL: "Prazosin, an adrenergic blocking agent inadequate as male contraceptive pill", CONTRACEPTION, GERON-X, INC., LOS ALTOS, CA, US, vol. 37, no. 6, 1 June 1988 (1988-06-01), pages 621-629, XP023167444, ISSN: 0010-7824, DOI: 10.1016/0010-7824(88)90008-X [retrieved on 1988-06-01]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).